AVANIR Pharmaceuticals Invites Investors to the Lazard Life Sciences Conference Webcast

SAN DIEGO--(BUSINESS WIRE)--Nov. 24, 2004--AVANIR Pharmaceuticals (AMEX:AVN) today announced that it will be presenting at the Lazard Life Sciences Conference and that the event will be webcast live through the Company's website at www.avanir.com. President and Chief Executive Officer Dr. Gerald J. Yakatan is scheduled to present at 1:30 pm Eastern time on November 30th at the conference in New York.

The live webcast will be accessible through AVANIR's corporate website. To access the webcast, please go to the home page of AVANIR's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. An archived version of the presentation will be available for 90 days following the conference and can be located in the Financials section of the website under Presentations.

AVANIR Pharmaceuticals is a drug discovery and development company focused on treatments for chronic diseases. Our product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.


    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, 858-622-5202
             psaxon@avanir.com

    SOURCE: Avanir Pharmaceuticals